Icariin inhibits inflammation via immunomodulation of the cutaneous hypothalamus–pituitary–adrenal axis in vitro. (1st March 2019)

• Record Type: Journal Article
• Authors: Kong, L.; Liang, X.; Liu, A.; Yang, X.; Luo, Q.; Lv, Y.; Dong, J.
• Is Part Of: Clinical and experimental dermatology. Volume 44:Number 2(2019)
• Page Start: 144
• Page End: 152
• Publication Date: 2019-03-01
• Subjects: Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/ced.13735
• Languages: English
• ISSNs: 0307-6938

Abstract

Summary: Background: Dysfunction of skin steroidogenesis plays an important role in inflammatory skin diseases. We previously carried out an animal study which showed that icariin could inhibit the inflammation of atopic dermatitis by regulating the cutaneous hypothalamus–pituitary–adrenal axis (HPAA). Aim: To explore the immunomodulation of icariin on cutaneous HPAA by detecting the response to the inflammatory cytokines tumour necrosis factor‐α/interferon‐γ in HaCaT cells. Methods: Cortisol level and the steroidogenesis‐regulating enzymes CYP11A1 and CYP11B1 were measured to evaluate the level of skin steroidogenesis. In addition, the therapeutic effects of blocking CRH‐R1 by the CRH‐R1 inhibitor antalarmin and blocking the CRH‐R1/2 signal pathway by the nonspecific CRH receptor antagonist astressin were observed. Results: Unexpectedly, we found that icariin treatment blocked the secretion of the inflammatory cytokines and prevented initiation of steroidogenesis; however, prolonged treatment with icariin significantly increased steroidogenesis in HaCaT cells. The promoting effect of icariin on steroidogenesis was not dependent on the CRH‐R1 pathway. Conclusion: Icariin has a regulatory effect on steroidogenesis in HaCaT cells, which may provide a promising therapeutic target for the treatment of inflammatory skin disorders.